Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity
Version of Record online: 16 FEB 2012
© 2012 John Wiley & Sons A/S
Journal of Pineal Research
Volume 53, Issue 2, pages 138–146, September 2012
How to Cite
Jeong, J.-K., Moon, M.-H., Lee, Y.-J., Seol, J.-W. and Park, S.-Y. (2012), Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. Journal of Pineal Research, 53: 138–146. doi: 10.1111/j.1600-079X.2012.00980.x
- Issue online: 13 AUG 2012
- Version of Record online: 16 FEB 2012
- Accepted manuscript online: 30 JAN 2012 03:03PM EST
- Received November 2, 2011; Accepted January 13, 2012.
- mitochondrial dysfunction;
- prion disease
Abstract: Melatonin has neuroprotective effects in the models of neurodegenerative disease including Alzheimer’s and Parkinson’s disease. Several studies have shown that melatonin prevents neurodegeneration by regulation of mitochondrial function. However, the protective action of melatonin has not been reported in prion disease. We investigated the influence of melatonin on prion-mediated neurotoxicity. Melatonin rescued neuronal cells from PrP(106–126)-induced neurotoxicity by prevention of mitochondrial dysfunction. Moreover, the protective effect of melatonin against mitochondrial dysfunction was related with autophagy activation. Melatonin-treated cells were dose-dependently increased in LC3-II, an autophagy marker. Melatonin-induced autophagy prevented a PrP(106–126)-induced reduction in mitochondrial potential and translocation of Bax to the mitochondria and cytochrome c release. On the other hand, downregulation of autophagy protein 5 with Atg5 siRNA or the autophagy blocker 3-methyladenine prevented the melatonin-mediated neuroprotective effects. This is the first report demonstrating that treatment with melatonin appears to protect against prion-mediated neurotoxicity and that the neuroprotection is induced by melatonin-mediated autophagy signals. The results of this study suggest that regulation of melatonin is a therapeutic strategy for prion peptide-induced apoptosis.